G1 Therapeutics, Inc.
NASDAQ:GTHX
Overview | Financials
Company Name | G1 Therapeutics, Inc. |
Symbol | GTHX |
Currency | USD |
Price | 7.16 |
Market Cap | 377,748,712 |
Dividend Yield | 0% |
52-week-range | 1.08 - 7.19 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. John E. Bailey Jr. |
Website | https://www.g1therapeutics.com |
An error occurred while fetching data.
About G1 Therapeutics, Inc.
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD